Drug stocks could see some downticks today, as shares of

Glaxo Wellcome

(GLX)

and

SmithKline Beecham

(SBH) - Get Report

were bid lower in premarket trading on news that their plans are suffering a setback.

On

Instinet

, Glaxo Wellcome was bid at $53.63, down 97 cents from Friday's closing price of $54.56, while SmithKline Beecham was bid at $60.50, off $1.31 from Friday's close of $61.81, reported

CNBC

. According to the companies, an investigation by

Federal Trade Commission

into their share of the quit-smoking market is causing the combination's delay.

Elsewhere,

Cyberonics

(CYBX)

was up 32 cents to $16.38 from Friday's closing price of $16.13 on Instinet, reported

The Wall Street Journal

.

Medtronic

(MDT) - Get Report

has launched an offer to buy the medical device maker, which specializes in treating epilepsy, for $480 million.

Stocks are set to head lower at the opening bell. The

S&P 500 futures on

Globex

lately were down 3.90 to 1515.10, about 2 points below fair value as calculated by

Prudential Securities

. Fair value is a good gauge of how stocks will perform in the early going.

Nasdaq 100

futures were off 29 to 3841.50, about 39 points below fair value, as calculated by

TheStreet.com

, and indicating that tech stocks are poised to open to the downside.

Europe's major indices were tentatively higher, with France's

CAC 40

off 0.4%, Germany's

Xetra Dax

down 0.8% and the U.K.'s

FTSE 100

0.9% lower. Japan's

Nikkei 225

lost 2.25% overnight, while Hong Kong's still-rallying

Hang Seng

slipped 1.55% (see today's

Asian Markets Update for more).